Medicine

New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis

Singapore Exchange (SGX) today welcomed Aoxin Q & M Dental Group Limited to Catalist under the stock code “1D4”.

- FIRST-QUARTER GAAP EPS FROM CONTINUING OPERATIONS OF $0.22; ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.48, ABOVE PREVIOUS GUIDANCE RANGE OF $0.42 TO $0.44

Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis

 

US FDA authorisation for Verona Pharma to proceed with clinical investigation of RPL554 with the acceptance of investigational new drug application

But effects of those differences are unclear.

Takeda Pharmaceutical Company Limited (TSE:4502) today announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications with a high unmet medical need

Accenture and BioCelerate Collaborate to Advance Biopharmaceutical Innovation Through Increased Insights in Research & Development

Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer

Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results

Improving consistency in the diagnosis of cervical pre-cancers: Roche CINtec Histology test receives FDA clearance

Market News alert UDG Healthcare Public Limited Co.

Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, today announced the launch of Bausch + Lomb ULTRA^® for Astigmatism contact lenses.

Amgen (NASDAQ:AMGN) and LabCentral announced that Cocoon Biotech, Torus Therapeutics, and Holobiome are the winners of Golden Ticket awards